Search Results - "Gafanov, Rustem A"

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma by McDermott, David F, Lee, Jae-Lyun, Bjarnason, Georg A, Larkin, James M G, Gafanov, Rustem A, Kochenderfer, Mark D, Jensen, Niels Viggo, Donskov, Frede, Malik, Jahangeer, Poprach, Alexandr, Tykodi, Scott S, Alonso-Gordoa, Teresa, Cho, Daniel C, Geertsen, Poul F, Climent Duran, Miguel Angel, DiSimone, Christopher, Silverman, Rachel Kloss, Perini, Rodolfo F, Schloss, Charles, Atkins, Michael B

“…Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II…”
Get full text

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial by Smith, Matthew R, Scher, Howard I, Sandhu, Shahneen, Efstathiou, Eleni, Lara, Primo N, Yu, Evan Y, Chi, Kim N, Ståhl, Olof, Olmos, David, Danila, Daniel C, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, Lopez-Gitlitz, Angela, Parnis, Francis, Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Ferguson, Thomas, Luyten, Daisy, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Mermershtain, Wilmosh, Peer, Avivit, Sella, Avishay, Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Choi, Young-Deuk, Gafanov, Rustem A., Kopyltsov, Evgeniy, Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Attard, Gerhardt, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Emamekhoo, Hamid, Pinski, Jacek K.

“…Metastatic castration-resistant prostate cancers are enriched for DNA repair gene defects (DRDs) that can be susceptible to synthetic lethality through…”
Get full text

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial by Tomczak, Piotr, Venugopal, Balaji, Ferguson, Thomas, Chang, Yen-Hwa, Gross-Goupil, Marine, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Choueiri, Toni K, Venugopal, Balaji, Lin, Tzu-Ping, Symeonides, Stefan N., Sawrycki, Piotr, Haas, Naomi B., Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Doshi, Gurjyot, Melichar, Bohuslav, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Menezes, Juliana de Janoski, Winquist, Eric W., Hamzaj, Alketa, Karaszewska, Boguslawa, Lipatov, Oleg N., McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Shkolnik, Michail I., McCune, Steven, Yeung, Carrie, Laguerre, Brigitte, Fomin, Eugeniy A., Zakharia, Yousef, Yorio, Jeffrey T., Yanez Ruiz, Eduardo, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Kato, Haruaki, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Feyerabend, Susan, Numakura, Kazuyuki, Zukov, Ruslan, Maroto Rey, Pablo Jose, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Hauke, Ralph, Jayram, Gautam, Estay, Angela, Rubiano, Juan Andres, Anai, Satoshi, Tsunemori, Hiroyuki, Sikora-Kupis, Bozena, Gunderson, Elizabeth, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Hanna, Nawar, Ibanez, Carolina, Manneh, Ray, Holeckova, Petra, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Goebell, Peter J., Hoefner, Thomas, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Szczylik, Cezary, Humphreys, Alison C., Kumar, Birendra, Karam, Jose Antonio, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Antonio Junior, Joao Neif, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Graham, Jeffrey, Borchiellini, Delphine, McDermott, Ray, Miura, Yuji, Prow, Debra M., Hashemi-Sadraei, Neda, Kendall, Stephan D.

“…The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in…”
Get full text